{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:26:35Z","timestamp":1790832395744,"version":"4.1.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009730","name":"Universidade Federal de Ouro Preto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017567","name":"Pr\u00f3-Reitoria de Pesquisa e P\u00f3s-Gradua\u00e7\u00e3o, Universidade Federal de Ouro Preto","doi-asserted-by":"publisher","award":["222019009"],"award-info":[{"award-number":["222019009"]}],"id":[{"id":"10.13039\/501100017567","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.xphs.2021.01.003","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T11:35:31Z","timestamp":1610537731000},"page":"1557-1571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Novel Insights to Enhance Therapeutics With Acyclovir in the Management of Herpes Simplex Encephalitis"],"prefix":"10.1016","volume":"110","author":[{"given":"Maria Silvia","family":"Gurgel Assis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taciane Cristina","family":"Fernandes Pedrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Segurasse","family":"de Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamires Guedes","family":"Caldeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gislaine Ribeiro","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Lu\u00eds Morais","family":"Ruela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2021.01.003_bib1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(79)92281-5","article-title":"Parenteral acyclovir therapy for herpesvirus infections in man","volume":"79","author":"Selby","year":"1979","journal-title":"Lancet"},{"issue":"1A","key":"10.1016\/j.xphs.2021.01.003_bib2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/0002-9343(82)90086-9","article-title":"Acyclovir tolerance in humans","volume":"73","author":"Keeney","year":"1982","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.xphs.2021.01.003_bib3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0190-9622(88)70022-5","article-title":"History, pharmacokinetics, and pharmacology of acyclovir","volume":"18","author":"King","year":"1988","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.xphs.2021.01.003_bib4","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1128\/AAC.19.4.608","article-title":"Single-dose pharmacokinetics of acyclovir","volume":"19","author":"Spector","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2021.01.003_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1023\/A:1023030210154","article-title":"Enhancement of nasal absorption of acyclovir via cyclodextrins","volume":"44","author":"Chavanpatil","year":"2002","journal-title":"J\u00a0Inclusion Phenom Macrocycl Chem"},{"issue":"3","key":"10.1016\/j.xphs.2021.01.003_bib6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1212\/CPJ.0000000000000036","article-title":"Diagnosis and management of acute encephalitis","volume":"4","author":"Venkatesan","year":"2014","journal-title":"Neurol Clin Pract"},{"issue":"11","key":"10.1016\/j.xphs.2021.01.003_bib7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.paed.2011.07.007","article-title":"Management and outcome in viral meningo-encephalitis","volume":"21","author":"Hartley","year":"2011","journal-title":"Paediatr Child Health"},{"key":"10.1016\/j.xphs.2021.01.003_bib8","first-page":"268","article-title":"Viral encephalitis","volume":"252","author":"Kennedy","year":"2005","journal-title":"J\u00a0Neurol"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0002-9343(93)90186-S","article-title":"Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose","volume":"92","author":"Haefeli","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.xphs.2021.01.003_bib10","series-title":"Drugs and Poisons. Clarke's Anal Drug Poisons Pharm Body Fluids Postmortem Mater","first-page":"2609","author":"Moffat","year":"2009"},{"issue":"12","key":"10.1016\/j.xphs.2021.01.003_bib11","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1002\/jps.21392","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Aciclovir","volume":"97","author":"Arnal","year":"2008","journal-title":"J\u00a0Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2021.01.003_bib12","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.21.5.804","article-title":"Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans","volume":"21","author":"Laskin","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.xphs.2021.01.003_bib13","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1021\/es903216p","article-title":"Antiviral drugs in wastewater and surface waters: a new pharmaceutical class of environmental relevance?","volume":"44","author":"Prasse","year":"2010","journal-title":"Environ Sci Technol"},{"issue":"1","key":"10.1016\/j.xphs.2021.01.003_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcv.2013.10.025","article-title":"Acyclovir-resistant herpes simplex encephalitis in a patient treated with anti-tumor necrosis factor-\u03b1 monoclonal antibodies","volume":"59","author":"Schepers","year":"2014","journal-title":"J\u00a0Clin Virol"},{"issue":"5","key":"10.1016\/j.xphs.2021.01.003_bib15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ369","article-title":"Herpes simplex encephalitis: lack of clinical benefit of long-term valacyclovir therapy","volume":"61","author":"Gnann","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"8405","key":"10.1016\/j.xphs.2021.01.003_bib16","first-page":"707","article-title":"Vidarabine versus acyclovir therapy in herpes simples encephalitis","volume":"2","author":"Whitley","year":"1986","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.xphs.2021.01.003_bib17","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jpeds.2015.01.023","article-title":"Intravenous acyclovir and renal dysfunction in children: a matched case control study","volume":"166","author":"Rao","year":"2015","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.xphs.2021.01.003_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0022-3476(05)81053-4","article-title":"Acyclovir therapy in neonates","volume":"119","author":"Englund","year":"1991","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1542\/peds.108.2.230","article-title":"Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections","volume":"108","author":"Kimberlin","year":"2001","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.xphs.2021.01.003_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/7.4.399","article-title":"Human pharmacokinetics of acyclovir (an antiviral agent) following rapid intravenous injection","volume":"7","author":"Brigden","year":"1981","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.xphs.2021.01.003_bib21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.1981.218","article-title":"Disposition of intravenous radioactive acyclovir","volume":"30","author":"de Miranda","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"1A","key":"10.1016\/j.xphs.2021.01.003_bib22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/0002-9343(82)90093-6","article-title":"Neonatal acyclovir pharmacokinetics in patients with herpes virus infections","volume":"73","author":"Hintz","year":"1982","journal-title":"Am J Med"},{"issue":"1A","key":"10.1016\/j.xphs.2021.01.003_bib23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0002-9343(82)90091-2","article-title":"Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure","volume":"73","author":"Krasny","year":"1982","journal-title":"Am J Med"},{"issue":"1A","key":"10.1016\/j.xphs.2021.01.003_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0002-9343(82)90084-5","article-title":"Pharmacokinetics of acyclovir in humans following intravenous administration: a model for the development of parenteral antivirals","volume":"73","author":"Whitley","year":"1982","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.xphs.2021.01.003_bib25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0272-6386(86)80193-7","article-title":"Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis","volume":"7","author":"Shah","year":"1986","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.xphs.2021.01.003_bib26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/clpt.1982.83","article-title":"Acyclovir kinetics in end-stage renal disease","volume":"31","author":"Laskin","year":"1982","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.xphs.2021.01.003_bib27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0002-9343(82)90090-0","article-title":"Effect of renal failure on the pharmacokinetics of acyclovir","volume":"73","author":"Laskin","year":"1982","journal-title":"Am J Med"},{"issue":"333","key":"10.1016\/j.xphs.2021.01.003_bib28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/01621459.1971.10482216","article-title":"Usefulness of the two-compartment open model in pharmacokinetics","volume":"66","author":"Metzler","year":"1971","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"6","key":"10.1016\/j.xphs.2021.01.003_bib29","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/cpt1979266718","article-title":"Acyclovir kinetics after intravenous infusion","volume":"26","author":"de Miranda","year":"1979","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.xphs.2021.01.003_bib30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/AAC.21.3.393","article-title":"Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans","volume":"21","author":"Laskin","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2021.01.003_bib31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0002-9343(82)90089-4","article-title":"Acyclovir clinical pharmacology: an overview","volume":"73","author":"Lietman","year":"1982","journal-title":"Am J Med"},{"issue":"Suppl B","key":"10.1016\/j.xphs.2021.01.003_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/12.suppl_B.29","article-title":"Pharmacokinetics of acyclovir after intravenous and oral administration","volume":"12","author":"de Miranda","year":"1983","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1A","key":"10.1016\/j.xphs.2021.01.003_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0002-9343(82)90088-2","article-title":"Overview of acyclovir pharmacokinetic disposition in adults and children","volume":"73","author":"Blum","year":"1982","journal-title":"Am J Med"},{"issue":"1A","key":"10.1016\/j.xphs.2021.01.003_bib34","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0002-9343(82)90094-8","article-title":"Metabolic fate of radioactive acyclovir in humans","volume":"73","author":"de Miranda","year":"1982","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.xphs.2021.01.003_bib35","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ijantimicag.2016.01.006","article-title":"Pharmacokinetics of acyclovir in a morbidly obese patient with renal impairment","volume":"47","author":"Smith","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0022-3565(25)32415-8","article-title":"Pharmacokinetics and bioavailability of acyclovir in the dog","volume":"216","author":"Krasny","year":"1981","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.xphs.2021.01.003_bib37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0002-9343(82)90095-X","article-title":"Acyclovir concentrations and tolerance during repetitive administration for 18 days","volume":"73","author":"Laskin","year":"1982","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.xphs.2021.01.003_bib38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0002-9343(82)90105-X","article-title":"Treatment of herpes virus infections in immunocompromised patients with acyclovir by continuous intravenous infusion","volume":"73","author":"Spector","year":"1982","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/phar.1526","article-title":"Therapeutic drug monitoring of continuous-infusion acylovir for disseminated herpes simplex virus infection in a neonate receiving concurrent extracorporeal life support and continuous renal replacement therapy","volume":"35","author":"Cies","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.xphs.2021.01.003_bib40","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/0002-9378(88)90033-6","article-title":"Acyclovir in human breast milk","volume":"158","author":"Meyer","year":"1988","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.xphs.2021.01.003_bib41","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine","volume":"74","author":"Elion","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8235","key":"10.1016\/j.xphs.2021.01.003_bib42","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(81)92570-8","article-title":"Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections","volume":"317","author":"Chou","year":"1981","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.xphs.2021.01.003_bib43","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0272-6386(12)70234-2","article-title":"Neurotoxicity of acyclovir in patients with end-stage renal failure treated with continuous ambulatory peritoneal dialysis","volume":"20","author":"Davenport","year":"1992","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.xphs.2021.01.003_bib44","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1073\/pnas.77.4.2270","article-title":"Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci","volume":"77","author":"Schnipper","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1A","key":"10.1016\/j.xphs.2021.01.003_bib45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0002-9343(82)90122-X","article-title":"Biochemical and genetic analysis of acyclovir-resistant mutants of herpes simplex virus type 1","volume":"73","author":"Coen","year":"1982","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0733-8635(02)00093-1","article-title":"Management of acyclovir-resistant herpes simplex virus","volume":"21","author":"Chilukuri","year":"2003","journal-title":"Dermatol Clin"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib47","doi-asserted-by":"crossref","first-page":"114935","DOI":"10.1016\/j.diagmicrobio.2019.114935","article-title":"Impact of the implementation of a rapid meningitis\/encephalitis multiplex polymerase chain reaction panel on IV acyclovir duration: multicenter, retrospective cohort of adult and pediatric patients","volume":"96","author":"Evans","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.xphs.2021.01.003_bib48","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1469-0691.2009.02735.x","article-title":"Factors associated with delay to acyclovir administration in 184 patients with herpes simplex virus encephalitis","volume":"15","author":"Poissy","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib49","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jemermed.2017.10.016","article-title":"During the emergency department evaluation of a well-appearing neonate with fever, should empiric acyclovir be initiated?","volume":"54","author":"Bruno","year":"2018","journal-title":"J\u00a0Emerg Med"},{"issue":"8405","key":"10.1016\/j.xphs.2021.01.003_bib50","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0140-6736(84)92623-0","article-title":"Acyclovir versus vidarabine in herpes simplex encephalitis: randomised multicentre study in consecutive Swedish patients","volume":"2","author":"Sk\u00f6ldenberg","year":"1984","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.xphs.2021.01.003_bib51","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1056\/NEJM199102143240703","article-title":"A\u00a0controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious diseases collaborative antiviral study group","volume":"324","author":"Whitley","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xphs.2021.01.003_bib52","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jiph.2016.06.010","article-title":"Prolonged acyclovir treatment in a child with opercular syndrome related to herpes simplex encephalitis","volume":"1","author":"Karli","year":"2017","journal-title":"J\u00a0Infect Public Health"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib53","first-page":"283","article-title":"Acyclovir in herpesvirus infections in children: experience in an open study with particular reference to safety","volume":"5","author":"Gould","year":"1982","journal-title":"J\u00a0Infect"},{"issue":"3","key":"10.1016\/j.xphs.2021.01.003_bib54","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1201-9712(98)90117-5","article-title":"Varicella pneumonitis: clinical presentation and experience with acyclovir treatment in immunocompetent adults","volume":"2","author":"El-Daher","year":"1998","journal-title":"Int J Infect Dis"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib55","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1164\/ajrccm\/136.2.402","article-title":"Prevention of lower respiratory herpes simplex virus infection with acyclovir in patients with adult respiratory distress syndrome","volume":"136","author":"Tuxen","year":"1987","journal-title":"Am Rev Respir Dis"},{"issue":"1 Suppl","key":"10.1016\/j.xphs.2021.01.003_bib56","first-page":"17","article-title":"Prophylactic studies against herpes infections in severely immunocompromised patients with acyclovir","volume":"6","author":"Prentice","year":"1983","journal-title":"J\u00a0Infect"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib57","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(85)92498-5","article-title":"Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B","volume":"17","author":"Schalm","year":"1985","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.xphs.2021.01.003_bib58","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0168-8278(86)80119-2","article-title":"Lymphoblastoid alpha-interferon weekly, daily and combined with acyclovir for chronic HBeAg-positive hepatitis","volume":"3","author":"Schalm","year":"1986","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.xphs.2021.01.003_bib59","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0168-8278(86)80113-1","article-title":"Treatment of chronic HBeAg-positive hepatitis with acyclovir. A controlled trial","volume":"3","author":"Guarascio","year":"1986","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.xphs.2021.01.003_bib60","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S0168-8278(86)80110-6","article-title":"A\u00a0controlled trial of acyclovir in stable chronic HBsAg, HBeAg-positive carriers","volume":"3","author":"Alexander","year":"1986","journal-title":"J\u00a0Hepatol"},{"issue":"2-3","key":"10.1016\/j.xphs.2021.01.003_bib61","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0168-8278(92)90175-O","article-title":"Failure of acyclovir to enhance the antiviral effect of \u03b1 lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B: a multi-centre randomized controlled trial","volume":"14","author":"Berk","year":"1992","journal-title":"J\u00a0Hepatol"},{"issue":"1A","key":"10.1016\/j.xphs.2021.01.003_bib62","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/0002-9343(82)90102-4","article-title":"Treatment of life-threatening Epstein-Barr virus infections with acyclovir","volume":"73","author":"Sullivan","year":"1982","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.xphs.2021.01.003_bib63","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0002-9343(82)90099-7","article-title":"Acyclovir in immunocompromised patients with cytomegalovirus disease: a controlled trial at one institution","volume":"73","author":"Balfour","year":"1982","journal-title":"Am J Med"},{"issue":"1A","key":"10.1016\/j.xphs.2021.01.003_bib64","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0002-9343(82)90100-0","article-title":"Treatment of cytomegalovirus pneumonia with high-dose acyclovir","volume":"73","author":"Wade","year":"1982","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.xphs.2021.01.003_bib65","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.bmt.1703770","article-title":"Ramdomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation","volume":"30","author":"Burns","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib66","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM198801143180202","article-title":"Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation","volume":"318","author":"Meyers","year":"1988","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib67","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.bmt.1700498","article-title":"Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection","volume":"19","author":"Prentice","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.xphs.2021.01.003_bib68","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00019048-199407000-00022","article-title":"Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation","volume":"3","author":"Fischer","year":"1994","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.xphs.2021.01.003_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2018.02.001","article-title":"Comparing treatment of acute retinal necrosis with either oral valaciclovir or intravenous aciclovir","volume":"188","author":"Baltinas","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.xphs.2021.01.003_bib70","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jmv.1890410513","article-title":"Safety of acyclovir: a summary of the first 10 years experience","author":"Tilson","year":"1993","journal-title":"J\u00a0Med Virol"},{"issue":"1A","key":"10.1016\/j.xphs.2021.01.003_bib71","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0002-9343(82)90097-3","article-title":"Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host","volume":"73","author":"Meyers","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.xphs.2021.01.003_bib72","first-page":"31","article-title":"High-dose intravenous acyclovir in the treatment of zoster: a double-blind, placebo-controlled trial","volume":"6","author":"Juel-Jensen","year":"1983","journal-title":"J\u00a0Infect"},{"issue":"3","key":"10.1016\/j.xphs.2021.01.003_bib73","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0002-9343(88)90578-5","article-title":"Intravenous acyclovir therapy of first episodes of genital herpes: a multicenter double-blind, placebo-controlled trial","volume":"85","author":"Peacock","year":"1988","journal-title":"Am J Med"},{"issue":"8290","key":"10.1016\/j.xphs.2021.01.003_bib74","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(82)91090-X","article-title":"Acyclovir therapy for acute herpes zoster","volume":"2","author":"Bean","year":"1982","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib75","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/infdis\/151.2.362","article-title":"Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster","volume":"151","author":"Bean","year":"1985","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.xphs.2021.01.003_bib76","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/0002-9343(87)90463-3","article-title":"Rapid response to acyclovir in herpes zoster-associated encephalitis","volume":"82","author":"Johns","year":"1987","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.xphs.2021.01.003_bib77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/014107689408700105","article-title":"The use of acyclovir in suspected encephalitis","volume":"87","author":"Gleadle","year":"1994","journal-title":"J\u00a0R Soc Med"},{"issue":"6","key":"10.1016\/j.xphs.2021.01.003_bib78","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00006454-198611000-00027","article-title":"Acyclovir crystalluria","volume":"5","author":"Peterslund","year":"1986","journal-title":"Pediatr Infect Dis"},{"issue":"4","key":"10.1016\/j.xphs.2021.01.003_bib79","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0272-6386(12)80939-5","article-title":"Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature","volume":"22","author":"Becker","year":"1993","journal-title":"Am J Kidney Dis"},{"issue":"1A","key":"10.1016\/j.xphs.2021.01.003_bib80","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0002-9343(82)90087-0","article-title":"Renal function after acyclovir intravenous injection","volume":"73","author":"Brigden","year":"1982","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.xphs.2021.01.003_bib81","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/FTD.0b013e31828faa35","article-title":"Differential diagnosis of central nervous system involvement in a patient treated with acyclovir","volume":"35","author":"Von Euler","year":"2013","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib82","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/157.2.385","article-title":"Excessive serum concentrations of acyclovir and neurotoxicity","volume":"157","author":"Feldman","year":"1988","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"10.1016\/j.xphs.2021.01.003_bib83","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0030-4220(84)90258-5","article-title":"Acyclovir and herpesvirus infections. A review of the literature","volume":"57","author":"Pallasch","year":"1984","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.xphs.2021.01.003_bib84","first-page":"3","article-title":"The mechanism of action, pharmacokinetics and toxicity of acyclovir - a review","volume":"6","author":"Brigden","year":"1983","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.xphs.2021.01.003_bib85","first-page":"177","article-title":"Doubling of serum creatinine and the risk of cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes mellitus: a cohort study","volume":"8","author":"Schneider","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.xphs.2021.01.003_bib86","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s10096-018-3332-5","article-title":"Incidence and predictors of intravenous acyclovir-induced nephrotoxicity","volume":"37","author":"Richelsen","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.xphs.2021.01.003_bib87","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/0886022X.2018.1487866","article-title":"The incidence, risk factors, and clinical outcomes of acute kidney injury (staged using the RIFLE classification) associated with intravenous acyclovir administration","volume":"40","author":"Lee","year":"2018","journal-title":"Ren Fail"},{"issue":"4","key":"10.1016\/j.xphs.2021.01.003_bib88","doi-asserted-by":"crossref","first-page":"ofz121","DOI":"10.1093\/ofid\/ofz121","article-title":"Impact of obesity on acyclovir-induced nephrotoxicity","volume":"6","author":"Barber","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.xphs.2021.01.003_bib89","doi-asserted-by":"crossref","first-page":"921","DOI":"10.7326\/0003-4819-98-6-921","article-title":"Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation","volume":"98","author":"Wade","year":"1983","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.xphs.2021.01.003_bib90","doi-asserted-by":"crossref","first-page":"101783","DOI":"10.1016\/j.jogoh.2020.101783","article-title":"Intravenous acyclovir-induced nephrotoxicity. Is pregnancy a risk factor?","volume":"49","author":"Boujenah","year":"2020","journal-title":"J\u00a0Gynecol Obstet Hum Reprod"},{"issue":"8","key":"10.1016\/j.xphs.2021.01.003_bib91","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1023\/A:1011919319810","article-title":"5\u2032-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter","volume":"15","author":"Han","year":"1998","journal-title":"Pharm Res (N Y)"},{"issue":"3","key":"10.1016\/j.xphs.2021.01.003_bib92","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1023\/A:1011901104421","article-title":"Negative correlation of n-octanol\/water partition coefficient and transport of some guanine derivatives through rat jejunum in\u00a0vitro","volume":"15","author":"Kristl","year":"1998","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.xphs.2021.01.003_bib93","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/03639040701655952","article-title":"In\u00a0vitro assessment of acyclovir permeation across cell monolayers in the presence of absorption enhancers","volume":"32","author":"Shah","year":"2008","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.xphs.2021.01.003_bib94","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/jphp.12551","article-title":"Effect of permeability enhancers on paracellular permeability of acyclovir","volume":"68","author":"Ates","year":"2016","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"12","key":"10.1016\/j.xphs.2021.01.003_bib95","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/jps.10245","article-title":"Preliminary pharmacokinetic study of different preparations of acyclovir with beta-cyclodextrin","volume":"91","author":"Luengo","year":"2002","journal-title":"J\u00a0Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2021.01.003_bib96","first-page":"1311","article-title":"Formulation and in\u00a0vitro evaluation of acyclovir loaded polymeric microparticles: a solubility enhancement study","volume":"73","author":"Mahmood","year":"2016","journal-title":"Acta Pol Pharm Drug Res"},{"issue":"10-12","key":"10.1016\/j.xphs.2021.01.003_bib97","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1080\/15257770008045444","article-title":"Guanosine analogues as anti-herpesvirus agents","volume":"19","author":"De Clercq","year":"2000","journal-title":"Nucleos Nucleot Nucleic Acids"},{"key":"10.1016\/j.xphs.2021.01.003_bib98","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/095632020101200505","article-title":"Antiviral activity of cyclosaligenyl prodrugs of acyclovir, carbovir and abacavir","volume":"12","author":"Balzarini","year":"2002","journal-title":"Antivir Chem Chemother"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib99","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0378-5173(94)90428-6","article-title":"Biodegradation characteristics of acyclovir 2\u2019-esters by respiratory carboxylesterases: implications in prodrug design for intranasal and pulmonary drug delivery","volume":"112","author":"Shao","year":"1994","journal-title":"Int J Pharm"},{"issue":"1-2","key":"10.1016\/j.xphs.2021.01.003_bib100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0378-5173(96)85199-4","article-title":"Analysis of in\u00a0vitro skin penetration of acyclovir prodrugs based on a diffusion model with a metabolic process","volume":"135","author":"Bando","year":"1996","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2021.01.003_bib101","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/1520-6017(200105)90:5<617::AID-JPS1018>3.0.CO;2-5","article-title":"Chemical stability, enzymatic hydrolysis, and nasal uptake of amino acid ester prodrugs of acyclovir","volume":"90","author":"Yang","year":"2001","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2021.01.003_bib102","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejps.2018.05.009","article-title":"Dissolving polymeric microneedle arrays for enhanced site-specific acyclovir delivery","volume":"121","author":"Pamornpathomkul","year":"2018","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2021.01.003_bib103","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ejpb.2007.07.005","article-title":"Liver targeting and anti-HBV activity of reconstituted HDL - acyclovir palmitate complex","volume":"68","author":"Feng","year":"2008","journal-title":"Eur J Pharm Biopharm"},{"issue":"7","key":"10.1016\/j.xphs.2021.01.003_bib104","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1128\/AAC.01023-10","article-title":"Valacyclovir for herpes simplex encephalitis","volume":"55","author":"Pouplin","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2021.01.003_bib105","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2002.119183","article-title":"Acyclovir concentrations in human breast milk after valaciclovir administration","volume":"186","author":"Sheffield","year":"2002","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.xphs.2021.01.003_bib106","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1128\/AAC.47.8.2438-2441.2003","article-title":"Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir","volume":"47","author":"Lycke","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2021.01.003_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0706446","article-title":"Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy","volume":"147","author":"De Clercq","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2021.01.003_bib108","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/jac\/dky568","article-title":"Valaciclovir therapy for herpes encephalitis: caution advised","volume":"74","author":"Bodilsen","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib109","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40121-017-0157-y","article-title":"Use of high-dose oral valacyclovir during an intravenous acyclovir shortage: a retrospective analysis of tolerability and drug shortage management","volume":"6","author":"McLaughlin","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"4-5","key":"10.1016\/j.xphs.2021.01.003_bib110","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ejps.2004.08.005","article-title":"Acyclovir prodrug for the intestinal di\/tri-peptide transporter PEPT1: comparison of in\u00a0vivo bioavailability in rats and transport in Caco-2 cells","volume":"23","author":"Thomsen","year":"2004","journal-title":"Eur J Pharm Sci"},{"issue":"1-2","key":"10.1016\/j.xphs.2021.01.003_bib111","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ijpharm.2017.07.024","article-title":"Functionalized PLA-PEG nanoparticles targeting intestinal transporter PepT1 for oral delivery of acyclovir","volume":"529","author":"Gourdon","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2021.01.003_bib112","doi-asserted-by":"crossref","first-page":"119638","DOI":"10.1016\/j.ijpharm.2020.119638","article-title":"A\u00a0novel cascade strategy using a nanonized targeted prodrug for enhanced oral delivery efficiency","volume":"587","author":"Guo","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2021.01.003_bib113","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.colsurfb.2009.08.050","article-title":"Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers","volume":"75","author":"Elshafeey","year":"2010","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"10","key":"10.1016\/j.xphs.2021.01.003_bib114","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/adhm.201300676","article-title":"Planar microdevices for enhanced in\u00a0vivo retention and oral bioavailability of poorly permeable drugs","volume":"3","author":"Chirra","year":"2014","journal-title":"Adv Healthc Mater"},{"issue":"2","key":"10.1016\/j.xphs.2021.01.003_bib115","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jps.23845","article-title":"Improved permeability of acyclovir: optimization of mucoadhesive liposomes using the phospholipid vesicle-based permeation assay","volume":"103","author":"Naderkhani","year":"2014","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2021.01.003_bib116","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.colsurfb.2015.10.045","article-title":"Formulation and evaluation of nano based drug delivery system for the buccal delivery of acyclovir","volume":"136","author":"Al-dhubiab","year":"2015","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.xphs.2021.01.003_bib117","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejps.2018.06.005","article-title":"Semisolid self-microemulsifying drug delivery systems (SMEDDSs): effects on pharmacokinetics of acyclovir in rats","volume":"121","author":"Djekic","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2021.01.003_bib118","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ijbiomac.2016.02.007","article-title":"Improving oral bioavailability of acyclovir using nanoparticulates of thiolated xyloglucan","volume":"89","author":"Madgulkar","year":"2016","journal-title":"Int J Biol Macromol"},{"issue":"March","key":"10.1016\/j.xphs.2021.01.003_bib119","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jddst.2019.02.031","article-title":"The effect of amphiphilic N, N, N-trimethyl-O-octadecyl chitosan on the oral bioavailability of acyclovir","volume":"51","author":"Chen","year":"2019","journal-title":"J\u00a0Drug Deliv Sci Technol"},{"key":"10.1016\/j.xphs.2021.01.003_bib120","doi-asserted-by":"crossref","first-page":"101634","DOI":"10.1016\/j.jddst.2020.101634","article-title":"Bilosomes nanocarriers for improved oral bioavailability of acyclovir: a complete characterization through in\u00a0vitro, ex-vivo and in\u00a0vivo assessment","volume":"57","author":"Saifi","year":"2020","journal-title":"J\u00a0Drug Deliv Sci Technol"},{"issue":"3","key":"10.1016\/j.xphs.2021.01.003_bib121","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ejpb.2004.01.001","article-title":"The influence of absorption enhancers on nasal absorption of acyclovir","volume":"57","author":"Chavanpatil","year":"2004","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"10.1016\/j.xphs.2021.01.003_bib122","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2133\/dmpk.22.206","article-title":"Influence of formulation viscosity on drug absorption following nasal application in rats","volume":"22","author":"Furubayashi","year":"2007","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.xphs.2021.01.003_bib123","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/10717540802035251","article-title":"Acyclovir liposomes for intranasal systemic delivery: development and pharmacokinetics evaluation","volume":"15","author":"Alsarra","year":"2008","journal-title":"Drug Deliv"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921000083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921000083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:33:31Z","timestamp":1758360811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921000083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":123,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0022354921000083"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.01.003","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Insights to Enhance Therapeutics With Acyclovir in the Management of Herpes Simplex Encephalitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}